Quest Diagnostics CEO sells $2.43M in stock

Quest Diagnostics’ CEO and President J. E. Davis sold 10,000 DGX shares under a Rule 10b5-1 trading plan, leaving him with 122,423 directly held shares.

Rhea-AI Filing Summary

QUEST DIAGNOSTICS INC (DGX) reported that CEO, President and director J. E. Davis sold 10,000 shares of common stock on September 1, 2026 at an average price of $242.72 per share in an open-market or private transaction. The transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the executive. Following this sale, Davis directly holds 122,423 shares of Quest Diagnostics common stock.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares

Net Sell 1 txn

Insider Davis J. E.

Role CEO and President

Sold 10,000 shs ($2.43M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	10,000	$242.72	$2.43M

Holdings After Transaction: Common Stock — 122,423 shares (Direct)

Footnotes (1)

1. F1. This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

Key Figures

Shares sold: 10,000 shares Sale price per share: $242.72 per share Implied gross sale proceeds: $2,427,200 +2 more

5 metrics

Shares sold 10,000 shares Common stock sale by J. E. Davis on September 1, 2026

Sale price per share $242.72 per share Average price for the 10,000 shares sold on September 1, 2026

Implied gross sale proceeds $2,427,200 10,000 shares sold at $242.72 per share

Shares held after transaction 122,423 shares Direct ownership of J. E. Davis following the September 1, 2026 sale

Number of reported sell transactions 1 transaction Non-derivative sale of common stock reported in this Form 4

Key Terms

Rule 10b5-1, open-market or private transaction

2 terms

Rule 10b5-1 regulatory

"effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open-market or private transaction financial

"Sale in open market or private transaction"

FAQ

What insider transaction did Quest Diagnostics (DGX) report for J. E. Davis?

Quest Diagnostics reported that CEO, President and director J. E. Davis sold 10,000 shares of common stock on September 1, 2026 at an average price of $242.72 per share in an open-market or private transaction.

How many Quest Diagnostics (DGX) shares does J. E. Davis hold after this sale?

After the reported sale, J. E. Davis directly holds 122,423 shares of Quest Diagnostics common stock. This figure reflects his direct ownership position immediately following the September 1, 2026 transaction.

Was the September 1, 2026 DGX stock sale by J. E. Davis under a Rule 10b5-1 plan?

Yes. The filing states that the sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by J. E. Davis, indicating the trades were pre-arranged under that plan.

What was the total value of the Quest Diagnostics (DGX) shares sold by J. E. Davis?

J. E. Davis sold 10,000 shares at an average price of $242.72 per share, implying gross sale proceeds of approximately $2.43 million for the September 1, 2026 transaction.

What is the role of J. E. Davis at Quest Diagnostics (DGX)?

J. E. Davis is reported as both CEO and President and as a director of Quest Diagnostics Inc., making him a senior executive officer and board member.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 05:51 PM Accepted by SEC EDGAR 09/03/2026 - 05:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis J. E.

(Last) (First) (Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS NEW JERSEY 07094

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		S(1)		10,000	D	$242.72	122,423	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

Remarks:

	Sean D. Mersten, Attorney in Fact for James E. Davis	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)